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Abstract
Background: Multiple myeloma (MM) is a fatal malignancy ranking second in prevalence among hematological
tumors. Continuous efforts are being made to develop innovative and more effective treatments. The preclinical
evaluation of new therapies relies on the use of murine models of the disease.
Methods: Here we describe a new MM animal model in NOD-Rag1null IL2rgnull (NRG) mice that supports the
engraftment of cell lines and primary MM cells that can be tracked with the tumor antigen, AKAP-4.
Results: Human MM cell lines, U266 and H929, and primary MM cells were successfully engrafted in NRG mice
after intravenous administration, and were found in the bone marrow, blood and spleen of tumor-challenged
animals. The AKAP-4 expression pattern was similar to that of known MM markers, such as paraproteins, CD38 and
CD45.
Conclusions: We developed for the first time a murine model allowing for the growth of both MM cell lines and
primary cells in multifocal sites, thus mimicking the disease seen in patients. Additionally, we validated the use of
AKAP-4 antigen to track tumor growth in vivo and to specifically identify MM cells in mouse tissues. We expect
that our model will significantly improve the pre-clinical evaluation of new anti-myeloma therapies.
Background
According to the American Cancer Society, more than
20,000 patients were diagnosed with multiple myeloma
(MM) in the US in 2010. Among hematologic malignan-
cies, MM ranks second in prevalence and has the short-
est 5-year survival rate [1]. Multiple myeloma (MM) is
an age-related cancer caused by the accumulation of
antibody-producing malignant plasma cells and leads to
progressive osteolysis, defective hematopoiesis and renal
failure [2]. Recent progresses in understanding the mole-
cular bases of MM have lead to the use of innovative
drugs, such as bortezomib, thalidomide and lenalido-
mide [3]. Unfortunately, although these therapies
afforded a significant improvement in the disease
course, MM remains invariably fatal because of the high
rate of multidrug-resistant relapse [4]. On these bases,
constant efforts are dedicated to the evaluation of more
effective treatment strategies [5-7].
Similarly to other malignancies [8], virtually any inno-
vative treatment for MM requires a pre-clinical assess-
ment, which largely relies on the use of animal models
to evaluate the anti-tumor potential and possible toxici-
ties [9-12]. To this goal, sub-lethally irradiated immuno-
deficient NOD/SCID mice have been extensively used
since they allow for human MM cell line xenografting
after intravenous injection [13-23]. More recently, it has
been shown that NOD/SCID mice carrying nonfunc-
tional IL-2 receptor gamma chain (NOD/SCID/gc
null,
NOG) are more permissive recipients than NOD/SCID
and can be easily xenografted with human MM cell
lines to produce a disease similar to that seen in
patients, including multiple metastatic sites and bone
lesions [24,25]. A further modification of the NOD
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and the IL-2 receptor gamma chain genes, namely
NOD-Rag1
null IL2rg
null (NRG), has been reported to tol-
erate higher levels of radiation compared with NOD/
SCID and NOG strains and to allow for efficient
engraftment of human hematopoietic stem cells [26].
The development of successful animal models for MM
also relies on the choice of the biomarkers used to track
the disease course and to identify tumor cells in mouse
tissues [27-32]. The A-kinase anchor protein 4 (AKAP-
4) [33] is a scaffolding protein that participates in the
intracellular signaling of protein kinase-A [34]. AKAP-4
is a cancer/testis antigen (CTA), a class of tumor asso-
ciated antigens characterized by high expression in germ
cells and cancer, strong immunogenicity and very low
expression or absence in normal tissues [35,36]. We
have previously shown that AKAP-4 is abnormally
expressed at the mRNA and protein levels in MM cell
lines and patients’ MM primary cells, but absent in nor-
mal tissues, and therefore it is a potential novel biomar-
ker for MM [37].
In this study, we used for the first time the NRG
strain to establish an innovative model of MM, allowing
for the growth and the spread of MM cell lines and pri-
mary patients’ cells as well. Additionally, we provide evi-
dence that the CTA AKAP-4 is a reliable and specific
biomarker that can be used to track the growth of MM
cell lines and primary cells in vivo.
Results
Detection of tumor growth in vivo by ELISA
Indirect ELISA was used to determine the concentration
of human paraproteins (IgE and IgG) and AKAP-4 in
the sera of tumor-bearing mice (Figure 1). Anti-human
IgE antibodies were used to monitor the growth of
U266 and H929 [38], since they are IgE-producing cell
lines. For MM primary cells, IgG was used as a parapro-
tein marker [39]. Figure 1 shows that paraprotein and
AKAP-4 levels became evident starting 21 days after
injection, and that a progressive increase was detectable
over time. Although AKAP-4 levels were on average
20% lower than IgE and IgG, no significant difference
between AKAP-4 and paraprotein mean levels was
detected at any time analyzed point (two-way ANOVA
and Bonferroni’s post-test p > 0.05).
Flow-cytometry identification of MM cells from mouse
tissues
Six weeks after initiation of tumor challenging, tumor-
bearing and healthy mice were euthanized, and tissues
were processed as described in the Methods section.
Flow cytometry analysis was performed to detect the
presence of MM cell lines or primary cells in the bone
marrow, blood and spleen (Figures 2, 3 and 4; Tables 1,
2, 3). Exponentially growing U266 and H929 cell lines
o rp r i m a r yc e l l sf r o mb o n em a r r o wa s p i r a t ew e r eu s e d
as positive controls (Figures 2 and 3; Tables 1, 2). IgE
was used as a marker for U266 and H929 [38], while
primary MM cells were identified by CD38 and CD54
[39]. AKAP-4 was expressed by MM cell lines (Figure 2;
Tables 1, 2) and primary MM cells (Figure 3; Table 3);
therefore it was tested for the detection of both cell
types. Results showed that IgE
+ U266 and H929 were
present in mouse bone marrow, blood and spleen (Fig-
ure 2; Tables 1, 2). Similarly, primary CD38
+ and CD54
+
primary MM cells were detected in bone marrow, blood
and spleen (Figure 3; Table 3). The expression pattern
of AKAP-4 was comparable to that of IgE, CD38 and
CD54 (Figures 2 and 3; Tables 1, 2, 3). The specificity of
the assay was confirmed by the failure to detect positive
cells in tumor-free mice (Figure 4).
Analysis of AKAP-4 expression at the mRNA and protein
levels in MM xenografts
RT-PCR was performed to evaluate AKAP-4 mRNA
expression in tumor-challenged or tumor-free mice.
Results (Figure 5) show that the AKAP-4 transcript was
present in MM cell lines, primary MM cells, bone
Figure 1 Measurement of circulating paraproteins and AKAP-4 levels. Mice were bled once a week as described in the Methods section.
The assay was run in triplicate for each time point. Graphs display mean protein levels obtained from each tumor group and error bars indicate
SEM. No statistically significant difference was evidenced between IgE or IgG and AKAP-4 levels at any of the analyzed time points as evaluated
by two-way ANOVA (Bonferroni’s post-test p > 0.05 for all comparisons).
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mice, but undetectable in tumor-free mice (healthy con-
trols). Specificity of results was also confirmed by PCR
reactions carried out without cDNA template or without
retrotranscribed RNA.
AKAP-4 protein was detected by Western blot analysis
(Figure 5) in MM cell lines, primary MM cells, bone
marrow, peripheral blood and spleens of tumor-bearing
mice, but not in tumor-free mice (healthy controls).
Discussion
This study was aimed to establish and characterize a
new murine model of disseminated MM, allowing for
the engraftment of human MM cell lines and primary
tumor cells derived from MM patients. To this goal, we
used the NOD-Rag1
null IL2rg
null (NRG) murine strain,
intravenously injected with MM cell lines or with pri-
mary MM cells. The lacking of a functional IL-2 recep-
tor makes IL2rg
null mice better xenograft recipients then
Figure 2 Detection of MM cell lines in tumor-bearing mice. U266 and H929 cell lines, or tissues derived from U266 and H929- injected mice
analyzed by flow-cytometry. Histograms show the fluorescence intensity measured with the indicated specific antibody (bold lines) or with the
corresponding isotypic control (dotted lines). Graphs are representative of comparable results obtained from 5 U266- and 5 H929-challenged mice.
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[38]. In addition, compared with NOD/SCID or NOD/
SCID/gc
null (NOG) strains, NRG mice tolerate signifi-
cantly higher levels of radiation. Differently from SCID
mice, the NRG strain carries a functional Prkdc gene,
which is essential for the repair of DNA damage
induced by radiation in many tissues [26].
ELISA for serum MM paraproteins showed that xeno-
grafted animals supported the growth of both MM cell
lines and primary tumor cells. Importantly, AKAP-4
was detectable in the sera of tumor-challenged mice
and its levels increased over time, similarly to those of
IgE and IgG. This indicates that AKAP-4 is a suitable
biomarker for tracking MM progression in murine
xenografts. Different techniques have been described to
monitor the MM burden in animal models, such as
fluorescent tagging of tumor cells [40-45] or measure-
ment of MM-derived paraptrotein in the serum [29-32].
In the clinic, better methods for staging and monitoring
the aggressiveness of MM, especially in assessing
relapse, are thought to be critical to improve patients’
outcomes and develop personalized therapies [46]. A
number of methods are under investigation, including
mass spectrometry for the quantification of serum
immunoglobulins [46], and immunohistochemistry for
the expression of FGFR3 and cyclin D1 (reported in
15%, and 50% of patients with MM, respectively)
[46,47]. In this context, the identification of novel
Figure 3 Detection of primary MM cells in tumor-bearing mice. Ficoll-hypaque isolated cells from primary bone aspirate, or cells derived
from primary MM-injected mice were analyzed by flow-cytometry. Histograms show the fluorescence intensity measured with the indicated
specific antibody (bold lines) or with the corresponding isotypic control (dotted lines). Histograms are representative of comparable results
obtained from 5 primary MM-challenged mice.
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more sensitive detection of disease progression [36].
Here we showed for the first time the use of AKAP-4
as a novel serum biomarker in MM animal models.
Further investigations are warranted to evaluate AKAP-
4 serum levels in MM patients and the correlation with
treatment outcome.
Flow-cytometry analysis confirmed the presence of
MM cell lines and primary patient’s cells in the bone
marrow, blood and spleen of tumor challenged mice,
indicating that intravenously injected tumor cells were
able to systemically disseminate in vivo. The specificity
of this finding was confirmed by the failure to detect
paraprotein- or AKAP-4- positive cells in tumor-free
Figure 4 Flow-cytometry evaluation of tumor-free mice. Six weeks after irradiation, healthy control mice were euthanized and processed in
parallel with tumor-bearing mice. Histograms show the fluorescence intensity measured with the indicated specific antibody (bold lines) or with
the corresponding isotypic control (dotted lines). Histograms are representative of comparable results obtained from 5 tumor-free mice.
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expressed in the same tissues at the transcriptional and
protein levels in tumor-bearing animals, but absent in
healthy controls. Collectively, these results indicate that
our model is suitable for the growth and systemic disse-
mination of human MM cell lines and primary tumors.
Currently available murine models for MM include
immunocompetent mice, such as the 5TMM series
[48,49] and genetic models of MM [50-52], or immuno-
compromised mice, namely NOD/SCID [13-23], SCID-
hu [53-56], and NOG [24,25,38,57]. The 5TMM and the
g e n e t i cm o d e l so fM Mh a v et h ea d v a n t a g eo fa f f o r d i n g
pre-clinical studies in immunocompetent hosts, where
possible effects of the therapy on the interaction
between tumor cells and the immune system can be
evaluated. However, molecular and biological differences
exist between murine and human MM cells [11]. Addi-
tionally, the number of available murine genetic models
of MM and of 5TMM cell lines is extremely restricted
and do not represent the heterogeneity of the human
disease [50-52,58,59]. Therefore, it is evident that pre-
clinical studies on MM cells of human origin are essen-
tial [9], but they are only feasible by using immunodefi-
cient murine xenografts. Among these, subcutaneous
inoculation of human MM cells has been extensively
described [13,17,45,60-62]. This model affords the possi-
bility to directly assess changing in tumor growth
induced by therapies. Yet, tumor cells growing subcuta-
neously do not interact with the bone marrow microen-
vironment, which largely accounts for MM drug
resistance [61,63]. Because we described the presence of
tumor cells in the bone marrow of tumor-challenge
mice, we propose that our model is suitable to evaluate
the protective role played by the bone niche against
anti-tumor therapies. Some concerns have been raised
about the possibility that the interactions between MM
cells and the bone stroma may be partially species-speci-
fic [11,64]. To address this potential difficulty, the SCID-
hu model was developed, in which MM cells are located
in subcutaneously implanted human bone chips [53-56].
Although SCID-hu mice allow for the growth of MM
cells in a bone niche of human origin [53-56], they do
not reproduce the pattern of dissemination and multifo-
cal spread seen in MM patients. Here we described for
the first time a murine model supporting the engraft-
ment human MM cells, and allowing for the develop-
ment of a disease involving multiple sites, similar to that
observed in patients [65-73]. This is an important
advantage, because the effect of bone resorption in mul-
tiple osteolytic lesions is a critical factor for the survival
of MM patients [6,7]. Pre-clinical studies basing on
immunocompromised xenograft models have previously
described metastatic spread involving multiple bones,
yet they have been limited to human MM cell lines
[40,41,43,44,74-76]. In this study, we show that our
model supports the metastatic growth of primary
human MM cells. MM cell lines do not adequately
represent the heterogeneity of the human disease
because they are established from late stage disease and
frequently present mutations not seen in patients [9].
Therefore, the possibility to study not only cell lines,
but also primary MM cells in murine models is relevant.
Conclusions
We presented here the proof-of-principle for the use of
NRG mice as a new model supporting the metastatic
growth of human MM cell lines and primary cells.
Additionally, we propose the use of AKAP4 as a univer-
sal biomarker to track tumor cells in vivo. We foresee
that our results will significantly contribute to the
improvement of the pre-clinical evaluation of new anti-
myeloma therapies. Because our model sustains the
growth of primary MM cells, further investigations are
warranted to study the suitability of this system to assess
the efficacy of personalized therapies directly on
patient’s cells.
Methods
Animals
Six-week-old female NOD.Cg-Rag1
tm1Mom IL2rg
tm1Wjl/
SzJ (NRG) mice were obtained from the Jackson Labora-
tory (Bar Harbor, ME, U.S.A.). All mice were maintained
in filtered-air laminar-flow cabinets under specific
pathogen-free conditions. Treatment and care of the
Table 1 Mean fluorescence intensity for U266 cells
Marker Cell line Bone marrow Blood Spleen
IgE 56.3
a (5.4)
b 48.7 (3.8) 25.4 (3.2) 19.7 (4.5)
AKAP-4 54.9 (3.3) 47.8 (7.6) 52.1 (6.4) 38.7 (4.5)
Mean fluorescent intensities (a) and SEM (b) were calculated by flow
cytometry from cells and tissues of 5 U266-challenged mice.
Table 2 Mean fluorescence intensity for H929 cells
Marker Cell line Bone marrow Blood Spleen
IgE 135.7
a (12.8)
b 49.6 (5.3) 46.2 (7.3) 128.9 (14.3)
AKAP-4 131.5 (7.6) 45.2 (8.1) 128.7 (5.7) 131.2 (6.4)
Mean fluorescent intensities (a) and SEM (b) were calculated by flow
cytometry from cells and tissues of 5 H929-challenged mice.
Table 3 Mean fluorescence intensity for primary MM cells
Marker Cell line Bone marrow Blood Spleen
CD38 98.9
a (11.2)
b 22.7 (6.7) 27.8 (8.4) 25.4 (4.7)
CD45 26.7 (3.1) 97.6 (7.6) 87.2 (4.1) 38.7 (2.1)
AKAP-4 98.6 (8.7) 88.4 (7.6) 33.2 (2.4) 47.6 (5.3)
Mean fluorescent intensities (a) and SEM (b) were calculated by flow
cytometry from cells and tissues of 5 primary MM-challenged mice.
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Guidelines and the Animal Welfare Assurance Act. The
mice were checked daily and euthanized 6 weeks after
tumor challenge or if they showed signs of excessive dis-
comfort (hind leg paralysis, inability to move, eat or
drink).
Human MM cell lines
The human MM cell lines U266 and H929 were pur-
chased from the American Type Culture Collection
(Manassas, VA, U.S.A.), and cultured in RPMI-1640
medium, supplemented with 10% V/V fetal bovine
serum (FBS) and penicillin/streptomycin mix (10 mg/
mL each) in 95% air and 5% CO2 at 37°C. Prior to injec-
tion, cells were washed once in PBS and then resus-
pended at 10
8 cells/mL in pre-warmed PBS prior to
injection.
Primary MM cells
Human material was obtained under informed consent
and with the approval from the local ethics committee.
Bone marrow aspirate was obtained from a MM patient
at diagnosis (Durie-Salmon stage III) from the hip bone.
Light density cells were separated by ficoll hypaque cen-
trifugation (Histopaque; Pharmacia, Uppsala, Sweden)
[39], washed twice in PBS, counted and adjusted at the
final concentration of 10
8 cells/mL in pre-warmed PBS
prior to injection.
Xenografts
20 mice were sub-lethally irradiated with a total dose of
550 cGy at 139 cGy/min rate [26]. After 6 hours, mice
were assigned to the following groups (5 mice/group):
group 1 received U266 cells, group 2 received H929,
group 3 was given primary MM cells, while group 4 was
Figure 5 RT-PCR/Western blot analyses of AKAP-4 mRNA/protein expressions and. RT-PCR analysis of mouse tissues was performed to
evaluate AKAP-4 expression. AKAP-4 was detected in bone marrow (BM), blood (BL) and spleen (SP) of mice injected with MM cell lines (U266,
H929) and primary tumor cells, but not in tumor-free mice. Positive controls were RNA isolated from exponentially in vitro growing cell lines, or
from primary cells after ficoll purification. For the evaluation of healthy mice, RNA isolated from human testis was used as a positive control.
Analysis of b-actin transcript served to confirm RNA integrity. Negative controls were PCR performed without template (No T), or with RNA not
subjected to the reverse transcription step (No RT). Proteins extracted from MM cells and mouse tissues were analyzed for the presence of AKAP-
4 protein by Western blot. AKAP-4 protein was detected in MM cell lines (U266 and H929), primary MM cells, and in the bone marrow, blood
and spleen of tumor-challenged mice, but not in healthy controls (tumor-free). Total protein extracts from human testis were used as a positive
control for the analysis of tumor-free mice. The pictures are representative of comparable results independently obtained from 5 mice in each
group.
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mouse received 10
7 cells by a single intravenous injec-
tion in the lateral tail vein (100 μL/mouse).
ELISA for the measurement of serum paraprotein and
AKAP-4 concentration
Blood (50 μL) was collected weekly from each mouse.
Serum was prepared by centrifugation in the absence of
anticoagulants and stored at -20°C until use. An
enzyme-linked immunosorbent assay (ELISA) was per-
formed on mouse sera for the determination of human
paraprotein (IgE and IgG) [39] or AKAP-4 concentra-
tion. Antibodies were purchased from BD Biosciences
(San Diego, CA, U.S.A.). 96-well polystyrene plates were
coated with serum (50 μL/well diluted 1:10 in carbonate
coating buffer), and incubated overnight at 4°C. Plates
were washed three times in PBS containing 0.05% (V/V)
Tween-20 (PBS/Tween) and then incubated in 1%
b o v i n es e r u ma l b u m i n( B S A )i nP B Sf o r1ha tR Tt o
block unspecific sites. After washing three times with
PBS/Tween, plates were incubated at 37°C with 50 μL/
well of primary anti-human IgE, IgG, or AKAP-4 anti-
bodies (5 μg/mL in PBS) for 1 h. After washing twice
with PBS/Tween, HRP-linked secondary antibody
(1:4,000 dilution in PBS, 50 μL/well, Santa Cruz Bio-
technology, CA, U.S.A.) was added and allowed to bind
for 60 minutes at RT. After washing trice with PBS/
Tween, 100 μL/well of TMP substrate (Abcam, Carpin-
teria, CA, U.S.A.) was added. The reaction was stopped
15 minutes later by adding 50 μL/well H2SO4 solution.
Optical density (OD) was measured with a Victor
2 plate
reader (PerkinElmer, Waltham, MA) at 450 nm. All
samples were analyzed in triplicates. Quantification of
the target antigens was made by interpolation of the
mean OD for each sample using a standard curve
obtained by 13 serial 3-fold dilutions (from 2,400 to 1.5
×1 0
-3 ng/mL) of purified human paraproteins (GenWay
Biotech, Inc., San Diego, CA, U.S.A.), or human AKAP-
4 (Abnova, CA, U.S.A.).
Preparation of tissues
Femurs, hips, sternums, and spleens were mechanically
disrupted in serum-free RPMI-1640 medium. Minced
organs were placed into 250 mL flasks containing 3 mL
of enzyme solution (0.14% collagenase type I; Sigma
Aldrich, MO, U.S.A.) and 0.01% DNase (2000 kU/mg;
Sigma Aldrich) in RPMI-1640 and incubated on a mag-
netic stirring apparatus at 37°C for 30 min. Then, cells
were washed in PBS and filtered through a nylon mesh
with 150 μm pores to generate single-cell suspensions.
Blood (500 μL) was taken by retro-orbital venipuncture
immediately after the euthanasia procedure and placed
in a heparin-coated tube. Cells were harvested by centri-
fugation and washed twice in PBS before analyses.
Flow-cytometry
The expression of human IgE, CD38, CD45 and AKAP-
4 was analyzed by flow-cytometry 6 weeks after tumor
injection as previously described [77]. Specifically, IgE
was used to identify U266 and H929 cells [38], while
CD38 and CD45 were used as markers for human MM
primary cells [39]. AKAP-4 was analyzed in both cell
lines and primary cells [37]. U266, H929, primary MM
cells and cells obtained from mouse bones, spleen and
blood were fixed with 2% W/V buffered PFA (Sigma-
Aldrich, MO, U.S.A) in PBS for 5 minutes at RT. After
washing with PBS, cells were permeabilized with 0.3%
saponin (Sigma-Aldrich, MO, U.S.A.) in PBS for 5 min-
utes at RT. After washing twice with PBS, cells were
incubated on ice with monoclonal antibodies raised
against human IgE, CD38, CD45 or AKAP-4 (Santa
Cruz Biotechnology, CA, U.S.A.) or isotypic controls for
1 hour. After washing twice with PBS, cells were incu-
bated with FITC-conjugated secondary antibodies (for
IgE, AKAP-4 and CD45), or PE-conjugated secondary
antibody (for CD38) (BD Biosciences, NJ, U.S.A.) for 1 h
on ice. Analysis was performed using a BD FACScan
( B DB i o s c i e n c e s ,N J ,U . S . A ) ,a f t e r3f i n a lw a s h i n gs t e p s
with PBS.
RT-PCR and immunoblot
Total RNA was extracted from bone, spleen, blood, or
from MM cell lines and primary MM cells by Trizol-
reagent (Sigma, St Louis, MO, U.S.A.). Purified total
RNA was treated with 5 μg RNase-free DNase I (Pro-
mega, Madison, WI, U.S.A.) at 37°C for 2 h. mRNA was
then isolated using Oligotex mRNA Mini Kit (QIAGEN,
Valencia, CA, U.S.A.). First-strand cDNA synthesis was
performed using oligo (dT) 15-mers primers. PCR pri-
mers for AKAP-4 were as follows: forward 5’-
GCGTACTCTGATACTACAATGATG -3’ and reverse
5’- GGG GTTTTGGGTAAAGTCA- 3’ [78]. PCR was
performed by 35 amplification cycles at 59°C annealing
temperature. For each sample, RNA integrity was
checked by amplification of the b-actin cDNA. Success-
ful removal of genomic DNA contamination was con-
firmed by amplification of the RNA without prior
reverse-transcription reaction. All results were con-
firmed in four independent RT-PCR tests. Immunoblots
for AKAP-4 were performed using standard methods, as
previously described [78]. Positive controls for immuno-
blots were proteins extracted from injected MM cells.
For healthy mice, protein extracts from human testis
were used as positive controls (Applied Biosystems, Fos-
ter City, CA, USA) [37].
Statistical analysis
All data are expressed as mean values ± SEM (Standard
Error of the Mean). Results were analyzed using
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USA.). Statistical analyses were performed by the two-
way ANOVA test. A p value < 0.05 was considered sta-
tistically significant.
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